Search

Your search keyword '"Kasai, Kana"' showing total 22 results
Start Over Author "Kasai, Kana"
22 results on '"Kasai, Kana"'

1. Expression of SMADs in orthotopic human endometrium, ovarian endometriosis, and endometriotic lesions in a murine model

Author

Kadota, Yuri, primary, Kato, Takeshi, additional, Kasai, Kana, additional, Kawakita, Takako, additional, Murayama, Misaki, additional, Shinya, Akari, additional, Sasada, Hikari, additional, Katayama, Sachiko, additional, Nii, Mari, additional, Yamamoto, Shota, additional, Noguchi, Hiroki, additional, Tamura, Kou, additional, Aoki, Hidenori, additional, Taniguchi, Miyu, additional, Nakagawa, Tomotaka, additional, Kaji, Takashi, additional, Nishimura, Masato, additional, Kinouchi, Riyo, additional, Yoshida, Kanako, additional, and Iwasa, Takeshi, additional

Published
2024
Full Text
View/download PDF

3. Effect of intraperitoneal docetaxel on ovarian function in mice

Author

Yoshida, Kanako, primary, Erdenebayar, Otgontsetseg, additional, Kadota, Yuri, additional, Kasai, Kana, additional, Kawakita, Takako, additional, Shinya, Akari, additional, Sasasda, Hikari, additional, Katayama, Sachiko, additional, Nii, Mari, additional, Imaizumi, Junki, additional, Kamada, Shuuhei, additional, Kagawa, Tomohiro, additional, Yoshida, Atsuko, additional, Yamamoto, Yuri, additional, Kato, Takeshi, additional, Irahara, Minoru, additional, and Iwasa, Takeshi, additional

Published
2022
Full Text
View/download PDF

4. Effects of oxytocin in postmenopausal rats

Author

Erdenebayar, Otgontsetseg, Kato, Takeshi, Kawakita, Takako, Kasai, Kana, Kadota, Yuri, Yoshida, Kanako, Iwasa, Takeshi, and Irahara, Minoru

Subjects
Adipocyte, peri- and postmenopause, Food intake, Menopause, Body weight, Oxytocin, feeding function, hormones, hormone substitutes, and hormone antagonists, metabolic function
Abstract

Recent studies have revealed that the administration of oxytocin has beneficial effects on the regulation of body weight, food intake, and metabolic functions, especially in obese individuals. Obesity is common in women after the menopause and drives many components of metabolic syndrome. Weight gain in menopausal women has been frequently reported. Although obesity and associated metabolic disorders are frequently observed in peri- and postmenopausal women, there are few medical interventions for these conditions. In this study, we evaluated the effects of chronic oxytocin administration on appetite, body weight, and fat mass in peri- and postmenopausal female rats. Sixteen naturally premenopausal or menopausal rats were intraperitoneally injected with oxytocin (1,000 μg/day) for 12 days. The daily changes in their body weight and food intake were measured at the same time as the oxytocin and vehicle injections. Intraperitoneally administering oxytocin for 12 days significantly reduced food intake, body weight, and visceral adipocyte size. In addition, oxytocin administration caused reductions in serum triglyceride and low-density lipoprotein-cholesterol levels, while it did not disturb hepatic or renal functions or locomotor activity. This is the first study to show the effects of oxytocin on the metabolic and feeding functions of peri- and postmenopausal female rats. Oxytocin might be a useful treatment for metabolic disorders caused by the menopause or aging.

Published
2021

5. 子宮内膜症モデルマウスにおいてアクチビンの腹腔内投与は子宮内膜症様病変の増殖を促進する

Author

Kasai, Kana, Kato, Takeshi, Kadota, Yuri, Erdenebayar, Otgontsetseg, Keyama, Kaoru, Kawakita, Takako, Yoshida, Kanako, Kuwahara, Akira, Matsuzaki, Toshiya, and Irahara, Minoru

Subjects
Inflammatory cytokine, Endometriosis, Activin A, Mouse model
Abstract

PURPOSE : This study aimed to investigate the effect of intraperitoneal administration of activin on the occurrence of endometriosis using a mouse model of endometriosis. METHODS : A mouse model of endometriosis was prepared by intraperitoneally administering endometrial tissue and blood collected from donor mice to C57BL/6J 7-8- week-old recipient mice. A total of 400 μg of activin A was intraperitoneally administered to model mice in the activin group for 5 days. Intraperitoneal endometriotic lesions were confirmed macroscopically and IL-6 and TNF-α levels in washed ascites were measured by ELISA. RESULTS : Endometriotic lesions were observed in all mice. In the activin group, the maximum diameter of endometriotic lesions was significantly larger than that in control group (4.7±1.3 vs 2.9±0.9 mm, p

Published
2019

6. 子宮内膜症モデルマウスにおいてLPSは腹膜子宮内膜症初期病巣形成を促進する

Author

Keyama, Kaoru, Kato, Takeshi, Kadota, Yuri, Erdenebayar, Otgontsetseg, Kasai, Kana, Kawakita, Takako, Tani, Anna, Matsui, Sumika, Iwasa, Takeshi, Yoshida, Kanako, Maegawa, Masahiko, Kuwahara, Akira, Matsuzaki, Toshiya, and Irahara, Minoru

Subjects
endometriosis, LPS, inflammation, cytokine, Murine model, mice model
Abstract

Purpose : The aims of this study were to clarify the effects of lipopolysaccharide (LPS) on the early development of endometriosis and on the production of cytokines and chemokines in the murine peritoneal cavity. Methods : Endometriotic lesions were induced in C57BL/6J adult female mice by intraperitoneal injection of endometrial fragments plus blood or endometrial fragments plus blood with LPS. On day 7, endometriotic lesions were assessed by gross and microscopic evaluations. Time-dependent changes in the secretion of TNF-α, IL-6, and CXCL2/MIP-2 in peritoneal lavage fluid after the intraperitoneal injection of LPS (50 µg/body) were measured by their respective enzyme-linked immunosorbent assays. Results : The areas of endometriotic lesions in the LPS group (10.8±8.6 mm2) were significantly larger than those in the control group (3.1±3.7 mm2). The levels of TNF-α and IL-6 peaked within 2 hours and the level of MIP-2 reached a maximum on day 1 after the injection of LPS. Conclusions : LPS promotes development of the early stages of murine endometriotic lesions.

Published
2019

10. Lipopolysaccharide promotes early endometrial-peritoneal interactions in a mouse model of endometriosis

Author

Keyama, Kaoru, primary, Kato, Takeshi, additional, Kadota, Yuri, additional, Erdenebayar, Otgontsetseg, additional, Kasai, Kana, additional, Kawakita, Takako, additional, Tani, Anna, additional, Matsui, Sumika, additional, Iwasa, Takeshi, additional, Yoshida, Kanako, additional, Maegawa, Masahiko, additional, Kuwahara, Akira, additional, Matsuzaki, Toshiya, additional, and Irahara, Minoru, additional

Published
2019
Full Text
View/download PDF

17. Circulating dehydroepiandrosterone-sulphate decreases even with a slight change in oestradiol.

Author

Matsui, Sumika, Yasui, Toshiyuki, Kasai, Kana, Yoshida, Kanako, Kato, Takeshi, Uemura, Hirokazu, Kuwahara, Akira, Matsuzaki, Toshiya, and Irahara, Minoru

Subjects
ESTRADIOL, HORMONE therapy for menopause, ESTROGEN, HYSTERECTOMY, SOMATOSTATIN, DEHYDROEPIANDROSTERONE, DRUG administration, FOLLICLE-stimulating hormone, HORMONES, LONGITUDINAL method, LUTEINIZING hormone, MENOPAUSE, ORAL drug administration, PROGESTATIONAL hormones, PROGESTERONE, THERAPEUTICS, TRANSDERMAL medication, CASE-control method
Abstract

The aim of this study was to determine the effect of hormone replacement therapy (HRT) on changes in circulating dehydroepiandrosterone-sulphate (DHEA-S) with focus on the relationship between oestrogen level and change in DHEA-S. Forty-two women were enrolled in this longitudinal study. Nineteen women received oral oestradiol and twenty-three women received transdermal oestradiol continuously. Twenty women received progesterone continuously except for women who had undergone hysterectomy. Circulating oestradiol, follicle-stimulating hormone, luteinising hormone and DHEA-S levels before and at 3 months after commencement of HRT were measured. Circulating DHEA-S level was significantly decreased at 3 months (p < .001). Oestradiol level at 3 months ranged from 6.5 pg/ml to 159 pg/ml. There was no significant correlation of ΔDHEA-S (DHEAS level at 3 months—DHEA-S level at baseline) with Δoestradiol (r = 0.114,p = .471). Circulating DHEA-S level was significantly decreased at 3 months in all the four quartiles and divided according to Δoestradiol, and ΔDHEA-S did not show significant differences. In conclusion, circulating DHEA-S decreases even with a slight increase in oestradiol level.Impact statementWhat is already known on this subject: A transient increase in DHEA-S in women during the menopausal transition may be involved in the occurrence of menopausal symptoms and/or unfavourable metabolic changes. Hormone replacement therapy decreases circulating DHEA-S level. However, dose dependency of the change in DHEA-S on oestrogen has not been reported.What the results of this study add: Circulating DHEA-S decreases even with a slight increase in oestradiol level.What the implications are of these findings for clinical practice and/or further research: Adrenal function may respond to a small change in oestrogen. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results